Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study
Author:
Affiliation:
1. Department of Dermatologic Oncology National Cancer Center Hospital Tokyo Japan
2. Department of Dermatology Cancer Institute Hospital of Japanese Foundation for Cancer Research Tokyo Japan
Funder
National Cancer Center
Publisher
Wiley
Subject
Dermatology,General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.15309
Reference26 articles.
1. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992–2006;Jemal A;J Am Acad Dermatol,2011
2. Characteristics of melanoma in Japan: a nationwide registry analysis 2011–2013
3. Final Version of 2009 AJCC Melanoma Staging and Classification
4. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation
5. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment;JAMA Dermatology;2023-10-01
2. Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity;Expert Review of Anticancer Therapy;2023-05-22
3. Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions;Melanoma Research;2022-10-07
4. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis;Frontiers in Oncology;2022-09-14
5. [Translated article] Characteristics, Management, and Prognostic Implications of Adverse Effects of Immune Checkpoint Inhibitors: A Systematic Review;Actas Dermo-Sifiliográficas;2022-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3